• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

AbbVie Receives Clearance from FDA on Once-Daily Chrohn’s Disease Pill

Article

Marks seventh approval for Rinvoq in the pharmaceutical field.

Crohn's disease word on tablet screen with medical equipment on background. Image Credit: Adobe Stock Images/japhoto

Image Credit: Adobe Stock Images/japhoto

AbbVie, a pharmaceutical organization, has received FDA approval for Rinvoq as a daily pill treatment for Crohn’s disease in adults. With this authorization, the medication has officially been approved seven time across rheumatology, dermatology, and gastroenterology, where it is shown in both ulcerative colitis and Crohn's disease.

"AbbVie recognizes the need for more treatment options for Crohn's disease that can help address both rapid relief of symptoms along with the visible reduction of intestinal lining damage," said Thomas Hudson, senior vice president, research and development, chief scientific officer, AbbVie. "We're pleased that RINVOQ may provide this relief and is now available to treat Crohn's disease."

Related Videos
Related Content